HomeCompareGHL vs PFE

GHL vs PFE: Dividend Comparison 2026

GHL yields 2.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.4K in total portfolio value· pulled ahead in Year 8
10 years
GHL
GHL
● Live price
2.67%
Share price
$14.99
Annual div
$0.40
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.1K
Annual income
$0.27
Full GHL calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GHL vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGHLPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GHL + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GHL pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GHL
Annual income on $10K today (after 15% tax)
$226.82/yr
After 10yr DRIP, annual income (after tax)
$0.23/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GHL + PFE for your $10,000?

GHL: 50%PFE: 50%
100% PFE50/50100% GHL
Portfolio after 10yr
$34.8K
Annual income
$13,129.49/yr
Blended yield
37.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GHL
Analyst Ratings
3
Buy
8
Hold
6
Sell
Consensus: Hold
Price Target
$8.50
-43.3% upside vs current
Range: $7.00 — $10.00
Altman Z
0.8
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GHL buys
0
PFE buys
0
No recent congressional trades found for GHL or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGHLPFE
Forward yield2.67%6.13%
Annual dividend / share$0.40$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$20.1K$49.6K
Annual income after 10y$0.27$26,258.71
Total dividends collected$269.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$8.50$27.50

Year-by-year: GHL vs PFE ($10,000, DRIP)

YearGHL PortfolioGHL Income/yrPFE PortfolioPFE Income/yrGap
1$10,833$133.42$9,153$693.39+$1.7KGHL
2$11,659$67.54$8,593$849.25+$3.1KGHL
3$12,509$33.97$8,336$1,066.78+$4.2KGHL
4$13,402$17.03$8,437$1,384.80+$5.0KGHL
5$14,349$8.53$9,013$1,875.40+$5.3KGHL
6$15,357$4.27$10,306$2,680.72+$5.1KGHL
7$16,435$2.13$12,820$4,101.38+$3.6KGHL
8← crossover$17,586$1.07$17,673$6,826.70$87.00PFE
9$18,818$0.53$27,543$12,591.86$8.7KPFE
10$20,135$0.27$49,560$26,258.71$29.4KPFE

GHL vs PFE: Complete Analysis 2026

GHLStock

Greenhill & Co., Inc., an independent investment bank, provides financial and strategic advisory services to corporations, partnerships, institutional investors, and governments worldwide. The company offers advisory services related to mergers and acquisitions, divestitures, restructurings, financings, private capital raising, and other similar transactions. It also advises clients on strategic matters, including activist shareholder defense, special committee projects, licensing deals, and joint ventures; and valuation, negotiation tactics, industry dynamics, structuring alternatives, and timing and pricing of transactions, as well as financing alternatives. In addition, the company provides restructuring advisory services to debtors, creditors, governments, and other stakeholders, and acquirers of distressed companies and assets; and advice on restructuring alternatives, capital structures, and sales or recapitalizations. Further, it assists clients in identifying and capitalizing on incremental sources of value; and on court-assisted reorganizations by developing and seeking approval for plans of reorganization, as well as the implementation of such plans. Additionally, the company advises on private placements of debt and structured equity, refinancing of existing debt facilities, negotiating the modification, and amendment of covenants, as well as acts as an independent advisor. It also offers financial advisory services to pension funds, endowments, and other institutional investors on transactions involving alternative assets; and advice to alternative asset fund sponsors for private capital raising, financing, restructuring, liquidity options, valuation, and related services. The company was founded in 1996 and is headquartered in New York, New York.

Full GHL Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GHL vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GHL vs SCHDGHL vs JEPIGHL vs OGHL vs KOGHL vs MAINGHL vs JNJGHL vs MRKGHL vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.